Enhancing immunogenicity without compromising safety is a central goal in modern immunoprophylaxis, and vaccine adjuvants and immunomodulators play a pivotal role in achieving it. These agents stimulate, direct, or modulate the immune response to improve vaccine efficacy, particularly in populations with weaker immunity such as the elderly or immunocompromised. From aluminum salts to saponin-based formulations and Toll-like receptor agonists, the landscape of adjuvants is expanding rapidly. Immunomodulators further fine-tune responses by influencing cytokine profiles, antigen presentation, and T-cell polarization. Beyond boosting responses, they contribute to dose sparing and cross-protection against antigenic variants. Safety profiling, compatibility with different antigen types, and long-term immunological outcomes remain critical aspects of ongoing research. As global attention shifts toward adaptable platforms, Vaccine adjuvants and immunomodulators are becoming integral to the success of next-generation vaccines addressing complex and evolving disease threats.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia